CorMedix Insider Buy Signals Confidence in DefenCath’s Sepsis Therapy
CorMedix insider buy shows confidence amid regulatory scrutiny; DefenCath offers a new sepsis therapy with solid safety data, but investors must watch CMS reimbursement and Phase III results for upside.
4 minutes to read